Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients

Autor: Chapuis, Nicolas, Ibrahimi, Nusaibah, Belmondo, Thibaut, Goulvestre, Claire, Berger, Anne-Emmanuelle, Mariaggi, Alice-Andrée, Andrieu, Muriel, Chenevier-Gobeaux, Camille, Bayle, Arnaud, Campos, Lydia, Cheurfa, Cherifa, Chocron, Richard, Diehl, Jean-Luc, Doumenc, Benoît, Duchemin, Jérôme, Duprat, Manon, François, Fabien, Gendron, Nicolas, Mirault, Tristant, Pène, Frédéric, Philippe, Aurélien, Pommeret, Fanny, Sanchez, Olivier, Smadja, David M., Szwebel, Tali-Anne, Silvin, Aymeric, Ginhoux, Florent, Lacroix, Ludovic, Jules-Clément, Gérôme, Rapeteramana, Sarobidy, Mavier, Colette, Steller, Laura, Perniconi, Barbara, André, Fabrice, Drubay, Damien, Fontenay, Michaela, Hüe, Sophie, Paul, Stéphane, Solary, Eric

Publikováno v: In eBioMedicine June 2022 80

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer.

Autor: Palafox, Marta, Monserrat, Laia, Bellet, Meritxell, Villacampa, Guillermo, Gonzalez-Perez, Abel, Oliveira, Mafalda, Brasó-Maristany, Fara, Ibrahimi, Nusaibah, Kannan, Srinivasaraghavan, Mina, Leonardo, Herrera-Abreu, Maria Teresa, Òdena, Andreu, Sánchez-Guixé, Mònica, Capelán, Marta, Azaro, Analía, Bruna, Alejandra, Rodríguez, Olga, Guzmán, Marta, Grueso, Judit, Viaplana, Cristina

Publikováno v: Nature Communications; 11/16/2022, Vol. 13 Issue 1, p1-20, 20p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER ⁺ breast cancer.

Autor: Palafox M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Monserrat L; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Bellet M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Villacampa G; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Gonzalez-Perez A; Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.; Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain., Oliveira M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Ibrahimi N; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.; Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France., Kannan S; Bioinformatics Institute (A*STAR), Singapore, Singapore., Mina L; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain., Herrera-Abreu MT; The Breast Cancer Now Research Centre, London, UK., Òdena A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Capelán M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Azaro A; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Bruna A; Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Viaplana C; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Hernández J; Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain., Su F; Novartis Pharmaceuticals, East Hanover, NJ, USA., Lin K; Genentech, Inc., South San Francisco, California, USA., Clarke RB; Breast Biology Group, Manchester Breast Centre, Manchester, UK., Caldas C; Cancer Research UK, Cambridge, UK., Arribas J; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Michiels S; Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.; Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France., García-Sanz A; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain., Turner NC; The Breast Cancer Now Research Centre, London, UK., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Department of Oncology, IOB Institute of Oncology, Barcelona, Spain., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Verma CS; Bioinformatics Institute (A*STAR), Singapore, Singapore.; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.; Department of Biological Sciences, National University of Singapore, Singapore, Singapore., Lopez-Bigas N; Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.; Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Scaltriti M; Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA., Arnedos M; Department of Medical Oncology, Gustave Roussy, Villejuif, France.; Inserm Unit U981, Villejuif, France., Saura C; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. vserra@vhio.net.; CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain. vserra@vhio.net.

Publikováno v: Nature communications [Nat Commun] 2022 Nov 14; Vol. 13 (1), pp. 6928. Date of Electronic Publication: 2022 Nov 14.